| Identification | Back Directory | [Name]
R-406 | [CAS]
841290-80-0 | [Synonyms]
R-406
CS-214
R406;R-406
R406(free base)
R-406 USP/EP/BP
R406 (Tamatinib)
R406 (FREE BASE);R-406
R406 (free base), >=98%
Fostamatinib (free base)
6-(5-Fluoro-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-ylamino)-2,2-dimethyl-2H-pyrido[3,2-b][
6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one
6-[5-Fluoro-2-(3,4,5-trimethoxy-phenylamino)-pyrimidin-4-ylamino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one
R406 6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one
6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-ylamino)-2,2-dimethyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one
6-[[5-Fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-2,2-dimethyl-2H-pyrido[3,2-b]-1,4-oxazin-3(4H)-one
2H-Pyrido[3,2-b]-1,4-oxazin-3(4H)-one, 6-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-2,2-dimethyl-
R-406 6-[[5-Fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-2,2-dimethyl-2H-pyrido[3,2-b]-1,4-oxazin-3(4H)-one | [EINECS(EC#)]
617-533-5 | [Molecular Formula]
C22H23FN6O5 | [MDL Number]
MFCD09970820 | [MOL File]
841290-80-0.mol | [Molecular Weight]
470.45 |
| Chemical Properties | Back Directory | [Melting point ]
182-184°C | [density ]
1.358±0.06 g/cm3(Predicted) | [storage temp. ]
Refrigerator | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
10.63±0.40(Predicted) | [color ]
Off-White to Light Grey | [InChI]
1S/C22H23FN6O5/c1-22(2)20(30)28-19-13(34-22)6-7-16(27-19)26-18-12(23)10-24-21(29-18)25-11-8-14(31-3)17(33-5)15(9-11)32-4/h6-10H,1-5H3,(H3,24,25,26,27,28,29,30) | [InChIKey]
NHHQJBCNYHBUSI-UHFFFAOYSA-N | [SMILES]
CC1(C(NC2=C(O1)C=CC(NC3=NC(NC4=CC(OC)=C(C(OC)=C4)OC)=NC=C3F)=N2)=O)C |
| Hazard Information | Back Directory | [Uses]
Intermediate used for preparation of prodrugs of pyrimidine-2,4-diamines as anticancer agents. | [Uses]
R406 is a potent ATP-competitive inhibitor of spleen tyrosine kinase (Syk, Ki = 30 nM). Through this action, R406 blocks FcεRI-dependent mast cell activation (EC50 = 43 nM) and, at 3 μM, reduces the release of IL-10, -12, and -13 by immune complex-pulsed dendritic cells. R406 is orally available and can reduce immune complex-mediated inflammation. In cancers characterized by over-expression of Syk, R406 can prevent signaling downstream of Syk and induce apoptosis. R406 also inhibits Syk-dependent signaling through c-Jun N-terminal kinase in rheumatoid arthritis synoviocytes, suggesting a therapeutic intervention in this autoimmune disease.[Cayman Chemical] | [Definition]
ChEBI:6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)-4-pyrimidinyl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one is a member of methoxybenzenes and a substituted aniline. | [Biological Activity]
r406 is a potent syk inhibitorspleen tyrosine kinase (syk) is a non-receptor tyrosine kinase mainly expressed in hematopoietic cells. it transmits signals from a variety of cell surface receptors including cd74, fc receptor and integrins. it is crucial for adaptive immune response, and also very important for cellular adhesion, innate immune recognition, osteoclast maturation, platelet activation and vascular development. [1]functional abnormality of syk has been implicated in several blood malignancies. constitutively active syk can transform b cells. syk inhibition can be beneficial for patients with blood cancers and autoimmune diseases.r406 is a potent inhibitor of ige and igg mediated fc receptor activation with ec50 for degranulation of 56-64 nm. [2] r406 targets syk and inhibits phosphorylation of syk substrates by binding to its atp binding pocket and competing with atp. r406 strongly inhibits syk kinase activity with an ic50 of 41 nm.r406 induces apoptosis in diffuse large b-cell lymphoma cell lines. it blocks b cell receptor signaling through inhibiton of syk autophosphorylation of y525/y526 and syk-dependent phosphorylation of the b-cell linker protein. [3]r406 can be administrated orally. | [Synthesis]
Step B: Preparation of 6-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one
Under nitrogen protection, 6-[(2-chloro-5-fluoropyrimidin-4-yl)amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one (product of step A, 568 kg, 1.00 mol eq.) was mixed with 3,4,5-trimethoxyaniline (402 kg, 1.25 mol eq.) in N-methylpyrrolidin-2-one ( 2835 kg) were mixed and stirred. After addition of water (11 kg), the reaction mixture was heated to 120 °C and maintained at this temperature with stirring for 10 hours. Upon completion of the reaction, the mixture was cooled to 65 °C and the pH was adjusted to 8.5 with a 4% w/w aqueous sodium hydroxide solution.Subsequently, the slurry was further cooled to 20 °C with continuous stirring for at least 6 hours and then filtered. The solid obtained by filtration was washed sequentially twice each with water (2 x 1440 kg) and acetone (2 x 1140 kg), and finally dried under vacuum at 40 °C to obtain the target compound 6-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-2,2-dimethyl-2H-pyrido[3,2-b]-1,4-oxazin-3(4H )-one (754 kg, 91% yield) as a colored solid.
1H NMR (400 MHz, DMSO-d6) δ ppm: 1.42 (s, 6H), 3.59 (s, 3H), 3.66 (s, 6H), 7.04 (s, 2H), 7.32 (d, J = 8.5 Hz, 1H), 7.68 (d, J = 8.5 Hz, 1H), 8.13 (d, J = 3.4 Hz, 1H), 9.10 (br.s, 1H), 9.14 (br.s, 1H), 11.06 (br.s, 1H).
Mass spectral data: m/z 471 [MH]+. | [in vivo]
R406 (5 and 10 mg/kg) shows efficacy in the amelioration of the Arthus reaction and in reducing clinical symptoms in the collagen antibody-induced arthritis (CAIA) and K/BxN models of rheumatoid arthritis (RA). Immune complex (IC)-mediated inflammation is reduced by inhibition of Fc receptor signaling with R406[1]. | Animal Model: | Female Balb/c mice (6-8 weeks) with CAIA[1] | | Dosage: | 5 and 10 mg/kg | | Administration: | Administered orally, b.i.d, for 14 days, starting 4 hours after antibody challenge on day 0. | | Result: | Reduced inflammation and swelling, and the arthritis progressed more slowly in treated animals than in vehicle controls. |
| Animal Model: | Female C57BL/6 mice with arthritis[1] | | Dosage: | 10 mg/kg | | Administration: | Administered orally one hour before serum injection; b.i.d; for 13 days | | Result: | Delayed the onset and reduced the severity of clinical arthritis. Paw thickening and clinical arthritis were reduced by approximately 50%. |
| [target]
Syk | [storage]
Store at -20°C | [References]
[1]mocsai a, ruland j, tybulewicz vl. the syk tyrosine kinase: a crucial player in diverse biological functions. nat rev immunol 2010. 10(6): 387-402.
[2]braselmann s, taylor v, zhao h, et al. r406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. j pharmacol exp ther 2006. 319(3): 998-1008.
[3]chen l, monti s, juszczynski p, et al. syk-dependent tonic b-cell receptor signaling is a rational treatment target in diffuse large b-cell lymphoma. blood 2008. 111(4): 2230*2237. |
|
| Company Name: |
J & K SCIENTIFIC LTD.
|
| Telephone: |
18210857532 18210857532 |
| Website: |
https://www.jkchemical.com |
| Company Name: |
NCE Biomedical Co.,Ltd.
|
| Telephone: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList15748/0_EN.htm |
|